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SUMMARY
Gene fusions are common cancer-causing muta-
tions, but the molecular principles by which fusion
protein products affect interaction networks and
cause disease are not well understood. Here, we
perform an integrative analysis of the structural, in-
teractomic, and regulatory properties of thousands
of putative fusion proteins. We demonstrate that
genes that form fusions (i.e., parent genes) tend to
be highly connected hub genes, whose protein prod-
ucts are enriched in structured and disordered inter-
action-mediating features. Fusion often results in the
loss of these parental features and the depletion of
regulatory sites such as post-translational modifica-
tions. Fusion products disproportionately connect
proteins that did not previously interact in the protein
interaction network. In this manner, fusion products
can escape cellular regulation and constitutively re-
wire protein interaction networks. We suggest that
the deregulation of central, interaction-prone pro-
teins may represent a widespread mechanism by
which fusion proteins alter the topology of cellular
signaling pathways and promote cancer.
INTRODUCTION
Fusion genes are hybrid genes formed from two previously inde-
pendent parent genes. Historically, gene fusions have been
viewed as common driver mutations in malignancies associated
with blood, lymph, and bone marrow tissue, but are becoming
increasingly recognized as important players in solid tumors
(Mertens et al., 2015a, 2015b; Yoshihara et al., 2015). For
example, translocation-induced gene fusions are found in about
90% of all lymphomas and over half of all leukemias (Lobato
et al., 2008), and the TMPRSS2-ERG fusion is the most frequent
genetic aberration in prostate cancer (Nam et al., 2007). In
accord with their important role in oncogenesis, fusion tran-
scripts and proteins have been utilized in many areas of clinical
care, from biomarker development and diagnostics to acting
as therapeutic targets (Kumar-Sinha et al., 2015; Mertens
et al., 2015b). Yet, aside from a relatively small number of well-
studied fusions, the functions of fusion proteins and the cellular
context in which they operate remain unclear.
A variety of mechanisms can lead to the fusion of two genes,
such as insertions, deletions, inversions, and translocations.
Continuous transcription of neighboring genes (Varley et al.,
2014) or trans- and cis-splicing of pre-mRNAs (Jividen and Li,
2014; Zhang et al., 2012) can also generate fusion transcripts
and proteins. If fusion transcripts are translated, the resulting
fusion proteins have the potential to redirect cellular signaling
pathways and act as principal oncogenic drivers (see Watson
et al., 2013; Yoshihara et al., 2015). Despite some concerns
over whether certain putative fusion mRNAs may be artifacts
of the sequencing procedure (Yu et al., 2014), the widespread
finding of recurrent gene fusions in tumor samples, the clinical
utility of an increasing number of gene fusions, and a growing
body of literature on fusion protein functionality adds support
to their potential for significant biological impact.
There are now approximately 10,000 known gene fusions,
most of which have only recently been discovered using deep
sequencing technology (Mertens et al., 2015a). The molecular
functions of gene fusions, and the fusion proteins they encode,
remain relatively poorly understood. Recent bioinformatics
work on gene fusions (reviewed in Latysheva and Babu, 2016)
has examined fusion protein domain content and recombination,
reading frame conservation, intrinsic disorder at fusion junctions,
and expression properties. However, the molecular principles of
fusion-mediated rewiring of protein networks and how fusion
proteins could disrupt native protein interactions remain unclear.
Here, we devise a genome-scale computational data analysis
framework to investigate the molecular principles by which
fusion proteins affect protein interactions (Figures 1A and 1B).
Understanding the structural features of fusion proteins, as
well as the interactions that are recurrently disrupted or created
as a result of fusion, will help clarify how fusions contribute to
specific cellular phenotypes and influence cancer initiation and
progression.
RESULTS
To compose a set of human fusion proteins, a list of fusion tran-
scripts from the ChiTaRS v1 database (Frenkel-Morgenstern
et al., 2013) was acquired andmapped onto Ensembl protein se-
quences (Experimental Procedures; Figure 1C). In this study,
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only fusions affecting protein-coding regions were examined. In
total, we mapped 2,699 distinct fusion proteins derived from
3,279 genes (Table S1; fusion protein mappings are available
as a web resource at http://fusion.d2p2.pro, integrated into the
D2P2 database; Oates et al., 2013). Genes that form fusions
(‘‘parent genes’’) are enriched for functions related to translation,
mRNA splicing, and the cell cycle, and for protein classes related
to translation, acetyltransferase activity, and the binding of actin,
A B
C
Figure 1. Study Outline
(A) Investigating how gene fusions and fusion proteins could affect molecular interactions in cancer.
(B) Summary of analyses employed.
(C) Description of processing procedure applied to the ChiTaRS database of fusion (‘‘chimeric’’) mRNA sequences to obtain a data set of fusion proteins.
See also Figures S1 and S2 and Table S1.
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chromatin, and RNA (Table S1). Parent genes that form multiple
fusions, especially five or more, are further enriched for functions
relating to translation, RNA binding, and nucleic acid binding.
Gene fusion events can be summarized as a network, in which
nodes indicate genes and a link between nodes indicates the
occurrence of a fusion between genes. Our resulting network
of gene fusions involving 3,209 genes (as gene symbols; Fig-
ure S1A) expands upon previous networks of300 gene fusions
(Ho¨glund et al., 2006;Mitelman et al., 2007); we confirm the pres-
ence of several major hubs, i.e., nodes with many edges (e.g.,
MLL, ETV6, NUP98, EWSR1, and ALK), and highlight novel
fusion hubs (e.g., COL1A1, HSP90AA1, MT1A, NCL, and
AFF1; Table S1; Figure S1A). The number of fusions formed for
each gene follows a power law distribution (Figure S1B), with
most parent genes forming few fusions (e.g., only 21 genes
form ten or more fusion proteins). Over a third of known onco-
genes (OGs) and a quarter of known tumor suppressor genes
(TSGs) form fusions in this data set (Figure S1).
Parent Proteins Have More Central Roles in Protein
Interaction Networks and Are Expressed at Higher
Levels
To examine whether parent genes encode proteins with central
positions in the human interactome, a high-confidence data
set of human protein-protein interactions (PPIs) (Wang et al.,
2012) was analyzed. In addition to a much higher number of
interaction partners (node degree; Figure 2A), parent proteins
have a significantly higher tendency to interconnect interaction
clusters, as quantified by betweenness centrality, which mea-
sures the extent to which a given node in a network lies on the
shortest paths between all other nodes (Figure 2B). Furthermore,
parent proteins have higher Kleinberg’s hub scores (see Experi-
mental Procedures), which measure a protein’s connection to
network hubs (Figure 2C). Compared to central non-parents,
the most central parent proteins were more likely to be involved
in functions such as mRNA splicing, cell proliferation, DNA repli-
cation, and repair (Table S2).
We observed that parent mRNAs and proteins are more abun-
dant compared to non-parents (3-fold difference between
averages; Figures S2A and S2B) in medulloblastoma cell lines
(Vogel et al., 2010). Additionally, parent proteins have very similar
half-lives to non-parent proteins (Figure S2C). Further, by inte-
grating data on 12 oncogenic signaling blocks (Cui et al.,
2007), we find that parent proteins are over twice as likely to
be involved in signaling processes implicated in oncogenesis
(c2 = 29.5, df = 1, and p = 5.7 3 108) (Figure S2D) and are
over 2.5 times as likely to be genes essential for cellular viability
(c2 = 396.8, df = 1, and p < 2.2 3 1016) (Figure S2E). Although
these trends need to be analyzed in different tissues, these re-
sults suggest that altering parent proteins could have a major
effect on critical cellular functions and for a sustained period
of time.
Parent genes were grouped into OG parent genes, TSG parent
genes, and all other parent genes (Figure S3A). Parent genes that
are neither OGs nor TSGs possess significantly higher network
centrality than non-parent genes, indicating that centrality is a
feature of parent genes more broadly and not simply reflective
of the centrality of OGs and TSGs. Further, parent OGs and
TSGs tend toward higher centrality than non-parent OGs and
TSGs, respectively (Figure S3B). For example, average centrality
measures for parent TSGs are approximately 30% higher than
non-parent TSGs. Replicate network centrality calculations on
two additional PPI data sets—the consensus network used in
further analyses (see below; Bossi and Lehner, 2009) (Fig-
ure S3C) and an unbiased interaction network derived using
mass spectrometry (Huttlin et al., 2015) (Figure S3D)—were
consistent with those described above.
Parent ProteinsHaveHigherCentrality in the Interaction
Networks of Cancer-Associated Cell and Tissue Types
Next, the role of parent proteins in tissue-specific protein interac-
tion networks (Bossi and Lehner, 2009) was examined. PPIs
involving parent proteins are present in more human tissues (me-
dian of 64 of 79 tissues, compared to 52 of 79 for non-parents;
p < 2.2 3 1016; Figure 2D), indicating that fusion events do
not only affect tissue-specific interactions. Parent proteins
consistently have on average 5 additional interaction partners
across most tissues (Figure 2E). Interestingly, the tissues and
cell types with the highest degrees for parent proteins—e.g.,
B and T cells, bone marrow cells, and blood cells—are cell types
often associated with fusion-induced cancers (gold dots, Fig-
ure 2E). Furthermore, parent proteins in the five cancer cell types
in the data set (teal dots) have on average 9.1% higher degree
than non-cancer cells and 12.1% higher degree than the set of
non-cancer and non-blood/bone/lymph cell types (Table S3).
This trend is not observed for betweenness (Figure S3E), but is
for hub scores (Figure S3F), whichmay indicate that gene fusions
in cancer may preferentially affect nodes of high degree (either
directly or indirectly) rather than alter global network cohesion.
Fusions could therefore be especially disruptive in tissues with
interaction networks containing proteins with unusually high de-
gree. Finally, fusion transcripts detected in cell lines of metasta-
tic tumor origin may have parent genes with higher centrality
compared to those fromprimary tumors (Figures S4A–S4D; Sup-
plemental Information), suggesting a possible connection be-
tween cancer aggressiveness and parent centrality. Although
this trend was not observed in the mass spectrometry PPI data
set (Huttlin et al., 2015; data not shown), the concept of a link
between cancer stage and the roles of parent proteins in PPI net-
works may be relevant in specific contexts (e.g., certain cancer
types).
Parent Proteins Are Unstructured and Enriched for
Interaction-Mediating Domains, which Are
Preferentially Excluded from Fusion Proteins
The structural features of parent proteins and their retention
within fusion proteins were investigated (Figures 3A–3L and
S5A–S5K). In agreement with a previous study (Hegyi et al.,
2009), parent proteins in our expanded data set (3,279 parent
proteins versus 406) have significantly higher intrinsic structural
disorder scores than non-parents (Figure S5A): OG parents have
on average 1.27 3 (0.39 versus 0.31; p = 2.8 3 104; and pair-
wise Wilcoxon rank-sum tests with Holmmultiple testing correc-
tion), TSG parents 1.15 3 (p = 1.5 3 103), and other parents
1.133 (p < 23 1016) higher disorder compared to non-parents.
Parent OGs and TSGs are approximately equally disordered as
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non-parent OGs and TSGs (Figure S5B), as are included versus
excluded fusion protein segments (Figure S5C). This suggests
that any observed enrichment of linear motifs and post-transla-
tional modifications (PTMs) in included segments (see below),
which are features correlated with disorder (Davey et al., 2012),
are not simply due to included segments being more disordered.
Throughout the structural feature calculations, densities instead
of counts are used to control for protein length.
Using a database of PPIs defined at the structurally resolved
level of domains (Meyer et al., 2013), we investigated parent
versus non-parent densities of interaction-mediating domains
(IMDs). Parent proteins, especially OG and TSG parent proteins,
have higher densities of IMDs (Figure 3A). On average,
compared to non-parent proteins, OG parents have 4.63, TSG
parents 2.73, and other parents 1.53 the IMD densities (all cor-
rected p values: <2.2 3 1016). There is a slight tendency for
parent OGs to have higher IMD densities than non-parent OGs
(on average 1.33; p = 9.1 3 103; Figure S5D). Hence, although
parent proteins are generally more intrinsically disordered, they
are also enriched in structured domains that mediate protein
interactions. IMDs tend to largely be excluded from fusion pro-
teins (Figure 3B; Table S4). OG parent proteins, in contrast to
A B C D
E
Figure 2. Network Centrality of Parent Genes and Proteins
(A–C) Parent genes possess more interaction partners in PPI networks (A), have higher betweenness centrality (B), and higher hub scores (C).
(D) PPIs involving parent proteins occur in more human tissues than interactions not involving parent proteins.
(E) The average number of interaction partners for parent proteins and all other proteins by tissue or cell type (gold = blood, bone marrow, and lymph tissues and
teal = cancer cells). Throughout this study, distribution outliers are excluded from boxplots for presentation purposes, but included in statistical analyses.
See also Figures S3 and S4 and Tables S2 and S3.
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TSG and other parent proteins, tend to retain IMDs upon fusion.
Overall, the most frequently retained IMDs include RNA-recogni-
tion, tyrosine kinase, pleckstrin homology (signaling and cyto-
skeleton), and SH3 and SH2 signaling domains (Table S4).
The average level of domain truncation upon transfer varies
significantly by domain type, and the most intact IMDs which
A B C D
E F G H
I J K L
Figure 3. Interaction-Mediating Molecular Features in Fusion Proteins
(A and B) IMDs in parent proteins (A) and fusion proteins (B).
(C and D) The PPI interface residues in parent proteins (C) and fusion proteins (D) are shown.
(E and F) The ELM LMs in parent proteins (E) and fusion proteins (F) are shown.
(G and H) The predicted ANCHOR LMs in parent proteins (G) and fusion proteins (H) are shown.
(I) The putative interaction-regulating PTMs in parent proteins are shown.
(J and K) Other PTM sites in parent proteins (J) and fusion proteins (K) are shown.
(L) The PTM type enrichments in included and excluded parent protein segments are shown. Within each subplot, Holm’s sequential Bonferroni correction for
multiple testing was applied.
See also Figure S5 and Tables S4 and S6.
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occur R10 times include ubiquitin conjugating domains, the
ubiquitin-like PB1 domain (a specificity adaptor to kinases),
and the proliferation modulating S_100 domain. Parents that
repeatedly donate large portions of IMDs are enriched for func-
tions in translation, cell structure morphogenesis, and cell cycle
and protein modification (Table S4).
Transfer of IMDs Can Create Novel Interactions and
Preserve Important Natural Interactions
The repeated inclusion of large portions of specific IMDs in
fusion proteins is interesting for two reasons (Figure 4A). First,
it can point to the importance of a particular domain-domain
interaction (DDI) for a fusion protein’s function. Second, as a
result of the fusion, a novel interaction-like link can occur be-
tween the interaction partner of the included domain and the
fusion partner. We map which domain-mediated PPIs are
repeatedly conserved in fusion proteins (Figures 4B and S6A;
Table S5). We find that 192 IMD-mediated PPIs are recurrently
retained in fusion proteins and comment on the most frequently
conserved DDIs (see the Figure S6A legend).
We also map novel protein links that are created through IMD
transfer (Figures 4C and S6B; Table S5). A protein interaction
‘‘link’’ was drawn between proteins A and B if there existed
some fusion protein B-C, where C normally interacts with A
and at least 90% of C’s IMD was retained (Figure 4A). Of the
126 novel links, 116 (92%) do not normally occur in the cell.
The most frequent novel links include many connections for
BCR, with the newly linked proteins being enriched for func-
tions in cell proliferation and cellular component movement
(Table S5), and 11 new connections for the nuclear trafficking
protein TPR, including eight tyrosine protein phosphatases
(Figures 4C and S6B). Certain fusion-induced novel links are
recurrent, e.g., fusion proteins involving both EML4 and TFG
lead to the gain of similar links (i.e., connections to receptor-
type protein tyrosine phosphatases PTPRB, PTPRG, and
PTPRJ).
Fusion-Generated Novel Links Disproportionately
Connect Proteins that Are Distant in the Interaction
Network
We examined the distance between the protein pairs in the novel
links set in a non-diseased PPI network. Where a path existed
between the novel links pairs, the distance was overall slightly
shorter than in other protein pairs in the network (Figure S6C).
However, fusion was found to disproportionately connect pro-
teins which normally reside in separate sections of the interac-
tome, whereas only 10.7% of protein pairs in the PPI network
had no connecting path, 29.3% of protein pairs in the novel links
set had no previous connecting path (Fisher’s exact test on con-
tingency table, odds ratio = 3.47, p = 3.0 3 108) (Figure S6D).
We examine the 34 newly connected protein pairs in Figure S6E
(see the legend).
Independent Structural Evidence Supports the Potential
of Fusion Proteins to Disrupt PPI, Protein-RNA
Interactions, and Protein-DNA Interactions
Structural interfaces in fusion proteins were identified by
analyzing the Protein Interfaces, Surfaces, and Assemblies
(PISA) database, which houses macromolecular interfaces
(involving proteins, RNA, and DNA) in the Protein Data Bank
(PDB). Parent proteins in the PDB contain more interface-form-
ing residues (Figure 3C). On average, 1.5% of residues in non-
parents form interfaces, and OG parents have on average
4.53, TSG parents 2.13, and other parents 2.03 this PISA res-
idue density. Parent OGs have 2.43 the average interface resi-
due density of non-parent OGs (p = 3.6 3 105; Figure S5E).
Interface residue densities on included and excluded segments
of parent proteins are similar (Figure 3D), though the distribution
is skewed toward exclusion (Figure S5F). The 302 parent pro-
teins which donate ten or more interface-forming residues to
fusion proteins are enriched for functions relating to cell cycle
signaling, carbohydrate and lipid metabolism, cellular compo-
nent morphogenesis, and cell death (Table S6).
Parent Proteins Are Enriched in Interaction-Mediating
Short Linear Motifs, which May Be Preferentially
Excluded from Fusion Products
Linear motifs (LMs) are short sequence motifs, usually <10 res-
idues, often found in intrinsically disordered regions (Tompa
et al., 2014). Using 1,410 experimentally validated LMs from
the ELM database (Dinkel et al., 2014) and over a million puta-
tive LMs identified using the ANCHOR program (Doszta´nyi
et al., 2009), we tested for enrichment of LMs within parent pro-
teins compared to all other proteins. Parent proteins have more
experimentally verified LMs on average (Figure 3E), with OG
and TSG parents harboring more motifs. Although most par-
ents have zero experimental LMs due to the small size of this
data set, on average, OG parents have 10.13 (p < 2 3
1016), TSG parents 7.13 (p < 2 3 1016), and other parents
1.33 (p = 8.0 3 1010) the LM density of non-parents. Parent
TSGs have slightly higher LM densities compared to non-
parent TSGs (Figure S5G). Fusion proteins tend to retain ELM
LMs, as shown by higher mean LM densities in included seg-
ments (Figure 3F). Parent proteins, which donate ELM LMs,
function in the regulation of cell death, the stress response,
protein metabolism, and nucleic acid binding (Table S6). Simi-
larly, the expanded ANCHOR data shows higher densities of
LMs in parents (Figure 3G), though parent OGs and TSGs
have similar densities to the non-parent categories (Figure S5H).
Interestingly, the larger ANCHOR data set shows a strong trend
toward the exclusion of LMs (Figure 3H). Either trend implies
that fusion substantially disrupts transient interactions medi-
ated by LMs.
PTMs that Regulate Protein Interactions Are Enriched in
Parent Proteins
We mapped putative interaction-regulating PTMs (PTMcode v2
database; Minguez et al., 2015) onto proteins and found that
compared to non-parents, OG parents have on average 4.63,
TSG parents 3.53, and other parents 2.23 the PTM density
(all corrected p < 2 3 1016; Figure 3I). Parent TSGs have
slightly more interaction-regulating PTMs compared to non-
parent TSGs (1.53, p = 0.03; Figure S5I). These PTM sites over-
all tend toward exclusion from fusion proteins (Figure S5J),
though the retention and loss is comparable in OG and TSG
parents.
584 Molecular Cell 63, 579–592, August 18, 2016
AB
C
Figure 4. Retained and Novel PPI in Fusion Proteins
(A) The repeated inclusion of large portions of specific IMDs in fusion proteins can lead to the retention of domain-mediated interactions or the creation of novel
interaction-like links between proteins.
(B and C) Subsets of the recurrently retained domain-mediated PPIs (B) and novel links (C) are shown.
See also Figure S6 and Table S5.
Molecular Cell 63, 579–592, August 18, 2016 585
Parent Proteins Are Enriched in PTM Sites, and Fusion
Proteins Tend to Selectively EscapeRegulation by PTMs
In addition to regulating protein interactions, post-translational
and co-translational modification sites can regulate protein
stability (e.g., by ubiquitination), subcellular localization (e.g.,
N-myristoylation), and protein function (e.g., acetylation). Parent
proteins have significantly more PTMs (Figure 3J) compared to
non-parents (on average 0.009 PTMs/residue): OG parents
have 3.53, TSG parents 3.53, and other parents 2.33 the
PTM densities of non-parents (all corrected p < 2 3 1016).
This suggests that the function, stability, and subcellular location
of parent proteins are extensively regulated by PTMs. Further, on
average, parent OGs have 1.53 (p = 7.53 103) the PTMcontent
of non-parent OGs, and parent TSGs have 2.13 (p = 1.43 105)
the PTM content of non-parent TSGs (Figure S5K). PTMs are
generally excluded from fusion proteins, though not in OG par-
ents (Figure 3K). The selective exclusion of PTM sites suggests
that fusion proteins tend to escape regulation by signaling path-
ways. TSG parents experience the heaviest loss of PTMs, with
excluded segments having over triple the median PTM density
of included segments (excluded: 0.022 PTMs/residue; included:
0.007; p = 3.03 104; Figure 3K). Parent proteins which retain at
least 90% of their PTM content are enriched for functions in
translation, ion transport, and metabolism (Table S6), while
parent proteins which lose at least 90% of their PTMs have a
wide range of functions, including splicing and cell matrix
adhesion.
Next, we examined the PTM profiles in included and excluded
fusion protein segments (Experimental Procedures; Figure 3L).
Certain PTM types (e.g., S-Nitrosylation) occur in either parental
segment more frequently than expected given the global fre-
quencies of all PTMs in dbPTM, while other PTM types (e.g.,
methylation and acetylation) showed marked presence/absence
patterns based on segment inclusion (Table S6).
Fusion Can Lead to the Gain and Loss of Ubiquitination
Sites, which May Deregulate the Activity of OGs
and TSGs
Ubiquitination (UB) sites are of particular interest since their loss
and gain upon fusion could ‘‘upregulate’’ OG activity or ‘‘down-
regulate’’ TSG activity, due to the role of UB sites in mediating
protein stability and degradation. We find 14 fusion proteins in
which OGs loseR5 UB sites and ten fusion proteins in which a
TSG gains R5 UB sites (Table 1). As an illustrative example,
we profile thewell-known EWSR1-FLI1 gene fusion fromEwing’s
sarcoma (Figure 5A). The specific pattern of segment retention in
EWSR1-FLI1 fusion proteins leads to UB site loss, which may
confer increased stability onto the fusion product, adding to
the known oncogenic mechanism of transcriptional deregula-
tion. Notably, decreased UB-mediated degradation of ETS fam-
ily transcription factors (e.g., FLI1) has been linked to cancer
(Vitari et al., 2011). Conversely, one of the most extreme exam-
ples of UB site gain by a TSG occurs in the previously unstudied
ATP50-TGFB1 fusion (Figure 5B), which results in the amalgam-
ation of a heavily ubiquitinated segment with a short portion of
the TGFB1 tumor suppressor domain, hinting at a fusion-medi-
ated loss of TSG function. TGF-b signaling is known to inhibit
cell proliferation and is normally tightly regulated by UB (Huang
and Chen, 2012). OG parents do not lose and TSG parents do
not gain UB sites more often than expected (data not shown),
but individual cases identified here (Table 1) could be of substan-
tial biological interest for follow-up studies.
Fusions Involving Transcription Factors Are Linked to
Significant Alterations in Downstream Target Gene
Expression Levels
To investigate the potential downstream network rewiring effects
due to fusion events, we investigated whether fusions involving
transcription factors (TFs) are associated with downstream
expression changes in the TFs’ regulatory targets. TCGA tumor
samples with TF-containing fusion transcripts and paired normal
controls were identified (Experimental Procedures). The regula-
tory target genes of TFs were acquired from the TRRUST data-
base (Han et al., 2015). Differential gene expression (DGE) values
were calculated (absolute log2 fold change between diseased
and healthy samples). The targets of TFs had significantly (i.e.,
corrected p < 0.05) higher DGE values in five of the eight paired
breast cancer samples when compared to all other genes (Fig-
ure S7). For example, four fusion transcripts containing TFs
were detected in patient TCGA-GI-A2C9; these four TFs
together affected 51 mapped regulatory targets, the mean (ab-
solute log2) DGE of which is 2.03 the mean DGE of all other
genes (Table S7; corrected p = 9.6 3 105). Across the eight
available biospecimen pairs, the average DGE of TF targets is
1.413 (mean) and 1.453 (median) the DGE of all other genes.
DISCUSSION
Many disease states result from altered dynamics of complex
regulatory and signaling interactions. Representing interactions
as networks provides a conceptual framework for understanding
how mutations in proteins can affect entire cellular systems and
cause disease (Wang et al., 2011; Wu et al., 2010), especially
when combined with structural analyses of interacting proteins
(Sudha et al., 2014; Wang et al., 2012). Here, we investigated
the interaction properties and structural features of thousands
of putative fusion proteins. Based on our observations, we delin-
eate genome-scale molecular principles by which gene fusions
can affect protein networks, rewire signaling pathways, and
contribute to disease (Figure 6). These trends will be useful for
setting novel gene fusions into context, building on the perfor-
mance of previous driver gene fusion prioritization algorithms
(Abate et al., 2014; Shugay et al., 2013), and interpreting studies
of fusion protein functionality.
Fusion Preferentially Affects Highly Central,
Interaction-Prone Proteins
Although it is likely that not all of the analyzed fusion proteins
drive disease (e.g., genomic instability can produce passenger
fusions; Mertens et al., 2015a), parent proteins are nonetheless
enriched for a wide variety of interaction-prone elements, such
as IMDs, interface-forming residues, LMs, and PTM sites that
regulate PPIs. The observed density of interaction-mediating
features in parent proteins is in accord with their centrality in
interaction networks. These results are consistent with other
computational work on disease mutations, which have shown
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Table 1. OGs LosingR5 UB Sites and Tumor Suppressor Genes GainingR5 UB Sites as a Result of Fusion Events
Fusion
Accessiona OG Description
Number of
UB Sites
Lost
Length of OG
Retained
Segment
Fusion
Partner Description of Fusion Partner
BF736842 EGFR epidermal growth factor receptor 17 25 SLC12A9 solute carrier family 12, member 9
AK098472 CTNNB1 catenin (cadherin-associated
protein), beta 1, and 88 kDa
9 420 RP11-
345J4.5
bolA-like protein 2
BE176861 COPS5 COP9 signalosome subunit 5 9 112 HNRNPH3 heterogeneous nuclear
ribonucleoprotein H3 (2H9)
BE176782 COPS5 COP9 signalosome subunit 5 9 112 HNRNPH3 heterogeneous nuclear
ribonucleoprotein H3 (2H9)
BG953255 CTTN cortactin 9 21 MYC v-myc avian myelocytomatosis
viral OG homolog
BP430745 CSE1L CSE1 chromosome segregation
1-like (yeast)
7 41 UGP2 UDP-glucose pyrophosphorylase 2
CN278368 TRIM32 tripartite motif-containing
protein 32
7 36 DDX21 DEAD (Asp-Glu-Ala-Asp) box
helicase 21
CV340327 ERBB2 v-erb-b2 avian erythroblastic
leukemia viral OG homolog 2
6 21 NOMO1 NODAL modulator 1
BE273347 DCUN1D1 DCN1, defective in cullin
neddylation 1, and domain
containing 1
6 24 QTRT1 queuine tRNA-ribosyltransferase 1
BC001010 CDK4 cyclin-dependent kinase 4 6 30 RPL4 ribosomal protein L4
AW371253 ERBB2 v-erb-b2 avian erythroblastic
leukemia viral OG homolog 2
5 49 RABGAP1 RAB GTPase activating protein 1
U08818 MET met proto-OG 5 380 MIR548F1 microRNA 548f-1
U19348 MET met proto-OG 5 380 MIR548F1 microRNA 548f-1
DA624159 TFG TRK-fused gene 5 90 GPR128 G protein-coupled receptor 128
Fusion
Accession
Tumor
Suppressor
Gene
Description Number of
UB Sites
Gained
Length of TSG
Retained
Segment
Fusion
Partner
Description of Fusion Partner
CD368725 TGFB1 transforming growth factor,
beta 1
13 45 ATP50 ATP synthase, H+ transporting,
mitochondrial F1 Complex, and
O subunit
DB041801 SMARCA4 SWI/SNF related, matrix
associated, actin dependent
regulator of chromatin,
subfamily a, and member 4
9 78 UBB ubiquitin B
BP213958 ARID1A AT rich interactive domain 1A
(SWI-like)
6 34 DNAJA2 DnaJ (Hsp40) homolog,
subfamily A, and member 2
DB120764 EEF1A1 eukaryotic translation elongation
factor 1 alpha 1
6 4 HIST1H2AM histone cluster 1, H2am
BG035867 EIF1 eukaryotic translation initiation
factor 1
6 38 RALY RALY heterogeneous nuclear
ribonucleoprotein
AB209020 GJA1 gap junction protein, alpha 1,
and 43 kDa
6 136 IFT140 intraflagellar transport 140
BG926120 PDCD4 programmed cell death 4
(neoplastic transformation
inhibitor)
5 110 GAPDH glyceraldehyde-3-phosphate
dehydrogenase
BC001412 EEF1A1 eukaryotic translation
elongation factor 1
alpha 1
5 462 LASP1 LIM and SH3 protein 1
BQ962146 E2F1 E2F TF 1 5 8 RDH11 retinol dehydrogenase 11
(all-trans/9-cis/11-cis)
CK004088 NDRG2 NDRG family member 2 5 153 RPL38 ribosomal protein L38
aChiTaRS fusion event accessions are listed along with affected genes, retained segment lengths, and tallies of UB site gain or loss.
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that disease-related in-frame mutations (Wang et al., 2012) and
disease-causing non-synonymous single nucleotide polymor-
phisms (David et al., 2012) are preferentially located on PPI inter-
faces. Finally, the finding that many parent genes are essential
genes dovetails with the concept of ‘‘edgetic’’ perturbations in
cancer, i.e., mutations that disrupt specific interactions (or
edges) of proteins rather than the entire node (Charloteaux
et al., 2011; Rolland et al., 2014; Wang et al., 2015), given that
disrupting essential genes is associated with lethality, fusion
may offer an opportunity to disrupt only a portion of an essential
protein’s function, such as specific interactions.
Network disruption may play a role in fusion proteins that first
appear to have relatively simple mechanisms of oncogenesis
(Figure 6A), for example, the concurrent rewiring of signaling
pathways can be critical for BCR-ABL1mediated transformation
(Pawson and Warner, 2007). Importantly, targeting the interact-
ing partners or downstream signaling of fusion proteins could
be a fruitful area for therapeutic agent development (see Tognon
et al., 2011). In this context, our observation that TF fusions
significantly perturb target gene expression in breast cancer
lends further weight to the signaling perturbation capabilities of
fusion events.
Fusion Results in a Loss of Parental Interaction-
Mediating Features and Regulatory Sites
Although parent proteins are enriched for interaction-mediating
features, the segments of parents that are included within fusion
proteins appear to be depleted of functional regions (though
OG parents retain more of these features than other parents).
Examining specific cases of fusion-mediated loss and gain of
molecular features (Figures 3A–3L), as well as interaction pres-
ervation and creation (Figures 4A–4C), is a rich resource for
hypothesis generation. For example, fusion proteins character-
ized by the repeated inclusion of largely complete tyrosine ki-
nase domains (e.g., Figure 6B) could be promising targets for
kinase inhibitors. Proteins dependent on the function of several
distinct molecular features (such as the interface residues and
nuclear import/export signal motifs in nucleophosmin; Fig-
ure 6B), as well as proteins sensitive to changes in PTM content
(such as EWSR1; Figure 6C), may be especially disrupted by
fusion events.
Although we largely addressed each interaction-mediating
and regulatory molecular feature of parent and fusion proteins
separately, these entities are not independent. For instance,
LMs tend to form interactions conditionally on PTM site status
A
B
Figure 5. Fusion-Induced UB Site Gain and Loss in Cancer-Associated Proteins
Fusion proteins involving OGs and TSGs can lead to the loss or gain of ubiquitination sites.
(A) Example of an OG losing UB sites upon fusion.
(B) Example of a TSG gaining UB sites upon fusion. The protein structure cartoons are of EWSR1 (PDB: 2CPE), FLI1 (PDB: 1FLI), and TGFB1 (PDB: 1KLA).
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(Van Roey et al., 2013). For example, the retinoic receptor alpha
gene (RARa) encodes a LM that acts as a phosphorylation-
dependent switch for binding Pin1. RARa forms driver fusion
proteins in acute promyelocytic leukemia, for which Pin1 sup-
pression is used as a treatment (Gianni et al., 2009). We find a
RARa fusion protein that excludes the LM in question (Figure 6C),
which could correspond to a treatment resistant patient. Knowl-
edge of the specific retained sequence of fusion proteins has
previously been observed to be key to patient treatment (Robin-
son et al., 2011).
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Figure 6. Molecular Principles by which Gene Fusions Can Alter Protein Interaction Networks in Cancer
(A) Fusion tends to involve highly central proteins in interaction networks and can alter networks by several mechanisms. Rewiring effects can play key roles in
seemingly straightforward fusion events, as in the constitutive kinase activation found in the BCR-ABL1 fusion.
(B and C) More generally, fusion can affect molecular interactions of proteins by shuffling interaction-prone regions within ordered (B) and disordered (C) protein
segments.
See also Figure S7 and Table S7.
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Conclusions
Our findings demonstrate that proteins that form fusions tend to
be highly interactive and positioned in critical regions of PPI net-
works. Disruption of such proteins may alter the topology of
signaling and regulatory pathways of cells and promote cancer.
A detailed understanding of the molecular impact of the rewired
network will be helpful for future drug discovery studies. For
example, in cases where driver fusion proteins retain the ability
to form interactions, their carcinogenic activity could be reduced
by the targeted disruption of specific interaction interfaces with
small molecules (Cierpicki and Grembecka, 2015; Jin et al.,
2014; Kuenemann et al., 2015). Additionally, recent methodolog-
ical advances in therapeutically degrading specific proteins
in vivo (Bondeson et al., 2015;Winter et al., 2015) could be instru-
mental to targeting oncogenic fusion proteins that have escaped
normal regulatory pathways.
EXPERIMENTAL PROCEDURES
Database Identification, Processing, and Integration
To compose a set of human fusion proteins, we acquired a database (ChiTaRS
v1 database; Frenkel-Morgenstern et al., 2013) of 9,237 fusion mRNAs. The
fusion transcripts were mapped onto known proteins in the Ensembl database
using ChiTaRS genomic coordinates and segments that mapped to non-
exonic regions (intronic, UTR, or intergenic sequences) were discarded. The
resulting data set maps all fusion protein segments defined at the DNA/
gene, mRNA, and protein levels (Table S1). We limit our analysis to fusion pro-
teins in which both parents were mapped to known Ensembl proteins. Fusion
protein mapping information is made available via a web server (http://www.
fusion.d2p2.pro). A fusion network of all gene fusions was constructed using
Cytoscape. Throughout this study, gene sets were tested for enrichments of
GO-Slim molecular functions and protein classes using PantherDB (Mi et al.,
2013). See the Supplemental Information for further methodological details.
mRNA and Protein Abundance and Half-Lives of Parents
Protein and mRNA abundances were acquired from a microarray and shotgun
proteomics study performed on the Daoy medulloblastoma cell line (Vogel
et al., 2010), and protein half-life data were taken from a SILAC study in HeLa
cells (Boisvert et al., 2012). These data sets were overlapped onto parent and
non-parent gene sets, and differences in distributions of abundance and half-
life by category were quantified by non-parametric Wilcoxon rank-sum tests.
Parent Gene Participation in Oncogenic Signaling Blocks
Disproportionate parent protein participation in cancer signaling processes
(Cui et al., 2007) was assessed using a contingency table and a chi-square
test of independence.
Parent Gene Essentiality
1,734 ‘‘core’’ essential genes shared between two cell lines (Blomen et al.,
2015) were acquired and tested for enrichment among parent genes as above.
PPI Network Centrality
Network centrality calculations for both parent and non-parent genes/proteins
were performed on a non-tissue specific PPI network (Wang et al., 2012) using
the igraph R package. See the Supplemental Information for definitions of cen-
trality measures. A tissue-specific PPI network (Bossi and Lehner, 2009) was
acquired in order to calculate tissue-specific PPI metrics (Buljan et al.,
2012). A more recent, expanded, and unbiased protein interaction data set
from human cells (Huttlin et al., 2015) was also investigated.
Intrinsic Structural Disorder in Parent Proteins
Residue-by-residue predictions for disorder for each protein in the human pro-
teome were generated using the IUPred program (Doszta´nyi et al., 2005;
http://www.iupred.enzim.hu/). Scores range from 0 to 1, where higher scores
indicate a higher propensity toward intrinsic disorder. Intrinsic disorder was
calculated for genes (i.e., longest isoform Ensembl protein) and for specific
included and excluded segments as an average over either the protein or
segment length.
Analysis of Interacting Domains within Proteins
A data set of curated, structurally resolved PPIs was acquired (Meyer et al.,
2013), and residues that form IMDs were mapped onto parent and non-parent
proteins. IMD retention was quantified by calculating IMD residue densities on
included and excluded segments. The frequency and completeness of reten-
tion of different domain types was summarized across the fusion protein set.
Statistically significant differences between gene sets in the distributions of
IMD residues were assessed as before. Parents which donate R20% of at
least one IMD were analyzed for functional and protein class enrichments.
Identifying Novel and Retained PPIs of Fusion Proteins
The above set of domain-mediating PPIs was analyzed to identify which PPIs
are recurrently (two or more times) retained in fusion proteins. DDIs were
deemed to be ‘‘retained’’ if at least one fusion protein incorporated at least
90% of the IMD. Novel interactions created as a result of the transfer of
IMDs were between protein A and B if there existed at least one fusion protein
B-C, where C normally interacts with A and at least 90% of C’s IMD was re-
tained. Novel links were those that did not appear in a set of known PPIs
(Wang et al., 2012).
Identifying Shortest Path Distances between Proteins Newly Linked
by Fusion
Pairwise shortest path lengths (geodesics) between all protein pairs in a PPI
network (Wang et al., 2012) were calculated using igraph. The distribution of
shortest path lengths in the novel link set was compared to the distribution
of path lengths in 1,000 randomly sampled protein pairs from the complete
geodesic matrix as before. Disconnected protein pairs had infinite shortest
path lengths, reflecting the absence of a geodesic. A contingency table
containing the counts of disconnected novel links versus other disconnected
protein pairs was constructed and tested for independence using Fisher’s
exact test.
Analysis of Interaction Interfaces in Parents
Structures of proteins in complex with proteins, DNA, or RNA molecules were
obtained from the PDB and PISA database (http://www.ebi.ac.uk/pdbe/pisa/).
Interface residues were identified and their positions converted into Ensembl
protein coordinates. PISA residue densities were calculated by counting
unique positions and dividing by protein lengths. Differences in the distribu-
tions of interface-forming PISA residue densities were analyzed as before. Bio-
logical process and protein class enrichments for parent genes that donate ten
or more interface-forming residues to fusion proteins were calculated.
Analysis of Short Linear Peptide Motifs in Parents
A set of 1,410 experimentally validated (Dinkel et al., 2014) and 1,036,282
computationally predicted (Doszta´nyi et al., 2009) LMs were acquired and
mapped onto proteins. LM densities were calculated by counting unique
ELM accessions and dividing by protein length. Differences in LM density
were assessed across parent gene sets and across included versus excluded
segments. Due to the small sample size of experimentally verified LMs, func-
tional enrichments were reported even if the number of genes in an enriched
category was less than ten. Parent proteins that donate LMs to fusion proteins
were assessed for functional enrichments.
Analysis of PTM Sites
PTM sites, which are candidate sites for regulating protein interactions, were
acquired from the PTMcode v2 data set (Minguez et al., 2015). Differences
in PTMcode site densities per gene were assessed for different parent gene
sets and across included versus excluded segments. Further, we obtained
and cleaned a data set of experimentally validated PTMs (dbPTM 3.0 data-
base; Lu et al., 2013). PTM densities were analyzed as before at the whole pro-
tein and fusion segment level. Enrichments of specific types of modification
sites were quantified in included and excluded segments.
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Analysis of TF Fusions and the Expression Levels of Target Genes
Fusion transcripts in TCGA samples (Yoshihara et al., 2015) were filtered to
identify fusions involving TFs (n = 1,131) (Table S7). The TCGA database
(Tomczak et al., 2015) was queried to identify matched RNaseq data for TF
fusion containing samples (n = 29). Normalized expression counts for each
matched sample pair were extracted, genes with extremely small read counts
(n < 10) removed, and DGE calculated as the absolute log2 fold change be-
tween the diseased and healthy samples. The regulated target genes of TFs
were acquired from the TRRUST database (Han et al., 2015). DGE values for
the TF targets were compared against all other genes using non-parametric
Wilcoxon rank-sum tests in cases where sufficient regulatory targets
(nR 20) were available (n = 8). The resulting p values were corrected for mul-
tiple testing using Holm’s procedure.
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